Introduction &
The hypothalamic-pituitary-adrenal (HPA) axis is the major hormone system responsible for maintaining homeostatic balance in response to stressful stimuli [1] . Appropriate regulatory control of the HPA axis is critical for health and survival, and several limbic brain structures, such as the hippocampus, amygdala, and prefrontal cortex, are involved in the integration of the HPA hormonal response [2, 3] . Activation of the stress system leads to behavioral and peripheral changes that improve the ability of the organism to adjust homeostasis and increase its chances for survival. The response of the endocrine system to stress is characterized by activation of the sympathetic adrenomedullary system with increased epinephrine secretion and by HPA axis activation with hypersecretion of adrenocortical hormones, particularly glucocorticoids. Aldosterone, the body ' s most potent mineralocorticoid, is secreted by the outer zone of the adrenal cortex, the zona glomerulosa. It plays an important role in blood pressure adjustment by regulating salt-water homeostasis [4] . HPA function [11] . Mice lacking cannabinoid receptor type 1 (CB1 − / − ) displayed a dysregulation of the HPA axis with a central impairment of glucocorticoid feedback and an enhanced circadian HPA axis activity peak resulting in elevated plasma corticosterone levels at the onset of dark [12 -14] . It is, however, unknown whether endocannabinoids infl uence adrenal glucocorticoid synthesis directly at the level of the adrenal in addition to their central eff ects. Furthermore, the CB1 receptor antagonist SR141716A has been shown to reduce blood pressure in obese patients; it is suggested that this is primarily mediated by the weight-reducing eff ect of the antagonist (for review [15] ). A possible direct eff ect on aldosterone secretion at the adrenal level, however, has not yet been studied. The present study, therefore, examines the expression of endocannabinoid receptors and possible eff ects of endocannabinoids on the release of cortisol and aldosterone in human adrenals and the human adrenocortical cell line NCI-H295R.
Materials and Methods

& Culture of NCI-H295R cells
As previously described [16] , NCI-H295R cells were cultured in DMEM / F12 (containing 33 μ M biotin, 17 μ M calcium D-pantothenate, 15 mM HEPES, 14 mM NaHCO 3 ), supplemented with insulin (66 nM), transferrin (10 μ g / ml), selenite (30 nM), penicillin (100 units / ml), streptomycin (100 μ g / ml), and 2 % FBS. NCI-H295R cells were grown in 75 cm 2 
Aldosterone and cortisol measurement
Aldosterone and cortisol in the incubation medium were measured by direct specifi c radioimmune assays (DSL-8 600; Diagnostic Systems Laboratories, Webster, TX, USA) according to the manufacturer ' s protocol.
RT-PCR
Human adrenal tissue was obtained from nephrectomies where the ipsilateral adrenal was removed with the kidney. Total RNA from harvested NCI-H295R cells, human adrenal tissue and peripheral blood mononuclear cells (PBMC) was isolated using RNeasy Plus Mini kits (Qiagen, Hilden, Germany) according to the manufacturer ' s instructions. Reverse transcription was performed with the reverse transcription buff er, RNase inhibitor, oligo(dT)15 primer, dNTP mix, and M-MLV reverse transcriptase at 37 ° C for 60 min according to the manufacturer ' s specifi cations (Promega, Madison, WI, USA). The PCR reactions were carried out with initial denaturation at 94 ° C for 4 min; 40 cycles amplifi cation at 94 ° C for 15 s, annealing for 15 s at 63 ° C (CB1) or 65 ° C (CB2), and elongation at 72 ° C for 15 s, followed by fi nal extension at 72 ° C for 1 min. . 3C ) secretion of cortisol was inhibited signifi cantly by AEA (p < 0.01 and p < 0.05, respectively). In accordance with previous data [17, 18] the maximal eff ective dose of AEA was 10 − 9 M with no further increase at higher doses. This inhibition of steroidogenesis was reversed by the CB1 antagonist SR141716A (SR; 10 Fig. 2 and 3 ) . Discussion & These data show that adrenocortical steroidogenesis within the human adrenal is directly infl uenced by the endocannabinoid system via CB1 receptors. Until a few years ago, the impact of cannabinoids on the HPA axis was considered to be an exception. Whereas the commonly accepted view attributes the cannabinoid system as having a general inhibitory role on neuroendocrine functions, it has been suggested that cannabinoids are, on the contrary, able to stimulate the HPA axis (for review [11] ). This concept was recently challenged, however, by several reports showing a diff erent action of endocannabinoids on the HPA axis. Specifi cally, it has been demonstrated repeatedly that acute treatment with the CB1 receptor antagonist SR141716A results in enhanced neuronal activation within the PVN and increased basal and stress-induced corticosterone secretion [19 -21] as well as anxiety-like behavior [22] . Other data indicate that the ECS might function as a gatekeeper of the HPA axis, exhibiting tonically high activity to suppress a persistent drive of the stress axis [23] . These investigations have demonstrated that endocannabinoids negatively modulate HPA axis activity in a context-dependent manner, thus reinforcing the idea initially proposed by Manzanares et al [24] that there is an endocannabinoid tone which exerts an inhibitory action over HPA axis activation [24, 25] . It is suggested that upon exposure to stress, endocannabinoid levels rapidly decline through an undetermined mechanism, resulting in a disinhibition of glutamatergic projections to the PVN and allowing activation of the HPA axis [25] . Consistent with the assumption that endogenous cannabinoids inhibit the HPA axis, several independent reports employing transgenic mice lacking the CB1 receptor (CB1 -/ -) have shown that these animals exhibit an enhanced HPA axis drive with an impaired glucocorticoid feedback [12 -14] . Pharmacological studies support this hypothesis and indicate that the changes in HPA axis activation in CB1 -/ -mice are not a result of developmental compensation for the loss of the receptor. Interestingly, the in vitro release of ACTH from anterior pituitary fragments is similar in CB1 -/ -and wild-type (WT) mice [13] indicating interactions of the endocannabinoids with the HPA axis at other levels than the pituitary. Previous studies focused on the interplay between the endocannabinoid system with the HPA axis at the central level. Our data indicate that, in addition to the central regulation of the HPA axis, endocannaboids via CB1 receptors directly inhibit adrenocortical steroidogenesis at the level of the adrenal. Human adrenal cortex expressed predominantly CB1 receptors. Similar to the normal human adrenal, the human adrenocortical cell line NCI-H295R expressed CB1 but not CB2 receptors. NCI-H295R cells are a widely accepted model for human adrenocortical studies and represent the only cell line able to produce all adrenocortical steroids and to express the three major pathways of adrenal steroidogenesis including the main steroidogenic enzymes. They have been used extensively to characterize the regulation of steroidogenesis including the regulation of aldosterone synthesis [26] . In the present study, these cells were used to analyze the eff ects of AEA and SR141716A on cortisol and aldosterone release. The CB1 agonist anandamide reduced basal as well as angiotensin II-and forskolin-stimulated cortisol and aldosterone secretion. Ang II stimulates adrenocortical steroidogenesis via inositol-1,3,4-phosphate [IP(3)] formation and subsequent Ca 2 + mobilization while forskolin is an activator of the PKA pathway. The inhibition of Ang II-and forskolin-induced steroidogenesis by AEA indicates an eff ect further downstream in steroid synthesis. The inhibitory eff ect of AEA was reversed by the concomitant incubation with the CB1 receptor antagonist SR141716A.
PCR: Primer sequences (5 -3 ' )
In conclusion, our data contributes further in vitro evidence for an interaction of the endocannabinoid system with adrenal steroidogenesis by inhibiting adrenal function directly at the level of the adrenal. This eff ect might, in addition to a central infl uence of endocannabinoids on HPA axis function, be relevant in glucocorticoid homeostasis. Furthermore, endocannabinoids might, in addition, infl uence blood pressure regulation by reducing aldosterone secretion from the adrenal.
